SCHEDULE 13D: Nutriband CEO Gareth Sheridan Discloses 17.73% Beneficial Ownership in Latest SEC Filing

Nutriband Inc.'s CEO, Gareth Sheridan, has filed a Schedule 13D disclosing a beneficial ownership of 17.73% of the company's common stock, held for investment purposes and including founder's shares and unexercised stock options.

Summary

• Gareth Sheridan, CEO of Nutriband Inc., has filed a Schedule 13D disclosing his beneficial ownership in the company.
• As of March 1, 2025, Mr. Sheridan beneficially owns an aggregate of 2,012,770 shares of Nutriband Inc. common stock.
• This represents 17.73% of the company's common stock, based on 11,154,171 shares outstanding as of March 1, 2025.
• His ownership includes 1,771,770 shares issued to him as founder's stock in connection with the company's formation in 2016.
• Additionally, he holds options to purchase an aggregate of 251,000 shares, granted between January 21, 2021, and January 23, 2025, with exercise prices ranging from $2.12 to $8.07.
• Mr. Sheridan has not yet exercised any of these options.
• The purpose of his holdings is for investment, with potential future actions including purchasing more shares or selling existing holdings based on market conditions and company performance.
• He may also engage in discussions with the Board and management regarding strategic matters, including potential business combinations, capital structure, and governance.

Sentiment

Score: 6

Explanation: The document is a standard Schedule 13D filing disclosing the CEO's beneficial ownership. The significant stake (17.73%) held by the CEO is generally viewed positively as it aligns management's interests with shareholders, but the filing itself does not contain new operational or financial news to significantly alter sentiment.

Positives

• The CEO's significant beneficial ownership of 17.73% aligns his interests with those of other shareholders, indicating strong insider commitment.
• The disclosure of founder's stock and compensation options provides transparency regarding the CEO's equity stake.

Risks

• The Reporting Person's future actions regarding the purchase or sale of shares will be dependent upon various factors, including price levels of common stock, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects, and the relative attractiveness of alternative business and investment opportunities.

Future Outlook

The Reporting Person expects to review investments in the Issuer and may, depending on market and other conditions, purchase additional shares or sell existing holdings. He may also engage in discussions with the Board and management concerning potential business combinations, strategic alternatives, capital structure, governance, and other matters.

Management Comments

• "The Reporting Person holds the common stock of the Issuer for investment purposes."
• "Depending on the factors discussed herein, the Reporting Person may, from time to time, acquire additional shares of common stock and/or retain and/or sell all or a portion of the shares of common stock held by the Reporting Person in the open market or in privately negotiated transactions, and/or may distribute the common stock held by the Reporting Person to other entities."
• "From time to time the Reporting Persons may engage in discussions with the Board and/or members of the Issuer's management team concerning, including, without limitation, potential business combinations and strategic alternatives, the business, operations, capital structure, governance, management, strategy of the Issuer and other matters concerning the Issuer."

Industry Context

This Schedule 13D filing is a standard disclosure of significant beneficial ownership by an insider (the CEO) in a publicly traded company. It highlights the CEO's continued commitment to the company within the medical device research and development sector, but does not provide specific details about broader industry trends.

Legal Proceedings

• The Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) during the last five years.
• Neither the Reporting Person nor any controlling persons were party to a civil proceeding of a judicial or administrative body that resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, U.S. federal or state securities laws, or finding any violations with respect to such laws, during the last five years.

Related Party Transactions

• 1,771,770 shares were issued to Gareth Sheridan as founder's stock in connection with the formation of the Company in 2016.
• The Company issued options to Gareth Sheridan to purchase an aggregate of 251,000 shares of common stock pursuant to the Issuer's stock option plan (amended and restated as of March 20, 2024), in various issuances at exercise prices from $2.12 to $8.07 in the period January 21, 2021 through January 23, 2025.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding the CEO's significant ownership stake, which can be seen as a positive signal of alignment between management and shareholder interests. The CEO's stated intent to potentially acquire more shares or engage in strategic discussions could influence future company direction.

Next Steps

• The Reporting Person may purchase additional shares of common stock or equity securities of the Issuer.
• The Reporting Person may sell all or a portion of the shares of common stock or related derivatives.
• The Reporting Person may engage in discussions with the Board and/or management concerning potential business combinations, strategic alternatives, capital structure, governance, management, and strategy.
• The Reporting Person may express views to the Board, management, or the public through social media or other channels.

Key Dates

Keywords

Nutriband Inc., Gareth Sheridan, Schedule 13D, Beneficial Ownership, Common Stock, SEC Filing, Insider Ownership, Stock Options, Founder's Stock, Medical Device Research and Development